Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan-Feb;19(1):17-29.
doi: 10.1111/j.1521-0391.2009.00004.x.

Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir

Jennifer Baker  1 , Petrie M Rainey, David E Moody, Gene D Morse, Qing Ma, Elinore F McCance-Katz
Affiliations

Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir

Jennifer Baker et al. Am J Addict. 2010 Jan-Feb.

Abstract

To improve outcomes among injection drug users with HIV and/or chronic hepatitis B, it is important to identify drug interactions between antiretroviral and opiate therapies. We report the results of a study designed to examine the interaction between buprenorphine and the nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine (ddI), lamivudine (3TC), and tenofovir (TDF). Opioid-dependent, buprenorphine/naloxone-maintained, HIV-negative volunteers (n = 27) participated in two 24-hour sessions to determine (1) pharmacokinetics of buprenorphine alone and (2) pharmacokinetics of both buprenorphine and either ddI, 3TC, or TDF. Among buprenorphine/naloxone-maintained study participants, no significant changes in buprenorphine pharmacokinetics were observed following ddI, 3TC, or TDF administration. Buprenorphine had no significant effect on NRTI concentrations. Concomitant use of buprenorphine with ddI, 3TC, or TDF results in neither a significant pharmacokinetic nor pharmacodynamic interaction.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Effect of didanosine on (a) buprenorphine, (b) norbuprenorphine, (c) buprenorphine-3-glucuronide, and (d) norbuprenorphine-3-glucuronide.
FIGURE 2
FIGURE 2
Effect of lamivudine on (a) buprenorphine, (b) norbuprenorphine, (c) buprenorphine-3-glucuronide, and (d) norbuprenorphine-3-glucuronide.
FIGURE 3
FIGURE 3
Effect of tenofovir on (a) buprenorphine, (b) norbuprenorphine, (c) buprenorphine-3-glucuronide, and (d) norbuprenorphine-3-glucuronide.
FIGURE 4
FIGURE 4
Effect of buprenorphine on (a) didanosine, (b) lamivudine, and (c) tenofovir.
See this image and copyright information in PMC

References

    1. UNAIDS [April 15, 2009]; Available at: http://www.unaids.org/en/knowledgecentre/hivdata/epidemiology/epislides.asp.
    1. Peters MG. Diagnosis and management of hepatitis B virus and HIV coinfection. Top HIV Med. 2007;15:163–166. - PubMed
    1. Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med. 2007;356:1445–1454. - PMC - PubMed
    1. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377–381. - PMC - PubMed
    1. Howard AA, Arnsten JH, Lo Y, et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS. 2002;16:2175–2182. - PubMed

Publication types